Bladder Cancer | Current Treatment: Physician Insights | US | 2022
Since the approval of immune checkpoint inhibitors, the treatment of bladder cancer has been transformed. Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) are now options in earlier settings, and Merck KGaA / Pfizer’s Bavencio will continue to be used in the first-line maintenance setting. The approval of novel drug classes for locally advanced unresectable or metastatic disease, such as Janssen’s first-in-class FGFR inhibitor Balversa (erdafitinib) for patients harboring susceptible FGFR2 or FGFR3 genetic alterations, and of antibody-drug conjugates (ADCs), such as Astellas / Seagen’s Padcev
(enfortumab vedotin-ejfv) and Gilead Sciences’ Trodelvy (sacituzumab govitecan), are further expanding physicians’ armamentarium and reshaping the treatment of bladder cancer.
Questions answered
- What percentage of high-risk non-muscle-invasive bladder cancer patients unresponsive to BCG receive Keytruda, and what is the treatment duration?
- How do drug-treatment rates vary across key patient populations and treatment lines?
- What is the uptake of immune checkpoint inhibitors in the United States across therapy lines? How are immune checkpoint inhibitors faring against older (e.g., platinum-based chemotherapy) and newer therapies (e.g.,Balversa, Padcev, Trodelvy)?
- What clinical factors drive the use of Bavencio as a first-line maintenance therapy for unresectable locally advanced or metastatic disease?
- What are the main drivers of and obstacles to treatment with key drugs for unresectable locally advanced or metastatic bladder cancer?
Product description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behaviour, and drivers of brand use so that marketers can create specific messaging around these treatment
dynamics to more effectively increase or defend their market position.
